Podcast: This Week in Managed Care—The $2 Million Gene Therapy and Other Health News
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This week, the top managed care news included the FDA's approval of a $2.1 million gene therapy; a study revealing that the worldwide need for palliative care will nearly double by 2060; the FDA granting priority review to Amarin’s Vascepa for a cardiovascular indication.
You may need to log in to the website to access this podcast.
Listen above or through one of these podcast services:
FDA Approves Gene Therapy With $2.1M Price Tag for Spinal Muscular Atrophy in Pediatric Patients
Amarin's High-Dose Fish Oil Pill Cuts Total CV Event Risk 30% in Study
The American Journal of Managed Care®—May 2019
Open Doors to Primary Care Should Add a “Screen” to Reduce Low-Value Care
American Society of Clinical Oncology Annual Meeting 2019
Read more about the stories in this podcast:
Sequencing of Treatment in Third-Line R/R LBCL
January 15th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the choice between treating patients with liso-cel or bispecific T-cell engagers.
